Cutaneous sarcoidosis: prognosis and treatment.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000367:Age Factors; D002216:Captopril / Q000627:therapeutic use; D002738:Chloroquine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007978:Levamisole / Q000627:therapeutic use; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D007703:Peptidyl-Dipeptidase A / Q000097:blood / Q000378:metabolism; D011379:Prognosis; D012507:Sarcoidosis / Q000188:drug therapy* / Q000201:enzymology / Q000276:immunology; D012871:Skin Diseases / Q000188:drug therapy* / Q000201:enzymology / Q000276:immunology; D014221:Triamcinolone / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D014221:Triamcinolone; D007978:Levamisole; D002738:Chloroquine; D002216:Captopril; D007703:Peptidyl-Dipeptidase A; D008727:Methotrexate